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Abstract
Mechanosensory hair cells of the organ of Corti transmit information regarding sound to the central
nervous system by way of peripheral afferent neurons. In return, the central nervous system provides
feedback and modulates the afferent stream of information through efferent neurons. The medial
olivocochlear efferent system makes direct synaptic contacts with outer hair cells and inhibits
amplification brought about by the active mechanical process inherent to these cells. This feedback
system offers the potential to improve the detection of signals in background noise, to selectively
attend to particular signals, and to protect the periphery from damage caused by overly loud sounds.
Acetylcholine released at the synapse between efferent terminals and outer hair cells activates a
peculiar nicotinic cholinergic receptor subtype, the α9α10 receptor. At present no
pharmacotherapeutic approaches have been designed that target this cholinergic receptor to treat
pathologies of the auditory system. The potential use of α9α10 selective drugs in conditions such as
noise-induced hearing loss, tinnitus and auditory processing disorders is discussed.
Keywords
nicotinic cholinergic receptors; noise trauma; cochlea; tinnitus; efferent feedback
1. Introduction
Sensory systems perform a series of common functions. Each system responds with some
specificity to a stimulus from the surrounding world and employs some specialized receptor
cells at the periphery to translate those stimuli into electrical signals that all neurons can
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understand. That initial electrical event begins the process by which the central nervous system
constructs an orderly representation of for example, sounds, odors, tastes and visual objects.
Thus, basic sound detection begins when sound waves strike the eardrum, which transmits that
physical stimulus to the organ of Corti within the cochlea, the sensory epithelium of the
mammalian inner ear. Here the primary receptor cells transform mechanical input into electrical
signals that are sent to the central nervous system by the auditory nerve [1]. However, unlike
vision, touch and the chemical senses, sound transduction is modulated by efferent signals
(olivocochlear, OC) that travel in reverse, from the brain back to the inner ear [2]. The present
work reviews the data which demonstrates that synaptic transmission between medial OC
(MOC) fibers and cochlear hair cells is mediated by a peculiar nicotinic cholinergic receptor
(nAChR), the α9α10 receptor. In addition, we discuss possible pharmacological targeting of
this receptor in inner ear pathologies, as well as in auditory processing disorders and reading
disabilities.
2. Organization of the mammalian cochlea
There are approximately 16,000 sensory hair cells in the human cochlea. They are organized
in a tonotopic fashion, with those sensitive to high frequency sound at the basal end and those
sensitive to low frequency at the apical end of the cochlear coil [1]. Hair cells are neuroepithelial
cells, with the apical pole specialized for mechanotransduction and the basal pole specialized
for the release of neurotransmitter. The mammalian cochlea contains two classes of hair cells
arranged in rows along the organ of Corti. Inner hair cells (IHCs), of which there are
approximately 3,500 in each human cochlea, are innervated by dendrites of the auditory nerve
and are considered to be the primary sensory hair cells of the cochlea. Outer hair cells (OHCs)
number approximately 11,000 in each human cochlea and lie in 3 rows. They have a much less
pronounced afferent innervation, but are the target of an efferent neural pathway [2-5]. IHCs
are also a target for a descending pathway, but in this case, the efferent axons form a synapse
on the postsynaptic (afferent) terminal and will not be considered further here.
3. Amplification in the mammalian ear
The receptor cells of most sensory organs must amplify their signals in order to separate them
from background noise. Photoreceptors, for example, use a biochemical cascade to enhance
their responses several thousand-fold after transduction has been accomplished. Cochlear hair
cells, instead use an active mechanical process to amplify their inputs [6,7]. When sound
reaches the cochlea, it elicits mechanical vibrations that are sensed and transduced into an
electrical response by motion of the hair bundles of hair cells which contain the mechanically-
gated ion channels. At the same time, however, the hair cells perform work by increasing the
magnitude of their mechanical input. This amplification of the stimulus constitutes a positive
feedback that enhances the sensitivity of hearing by countering the loss of energy through the
viscous dissipation that accompanies the motion of hair bundles and other structures through
the fluids of the inner ear.
There is little debate that in mammals OHCs are the principal players providing the feedback
that drives cochlear amplification. Two alternative mechanisms for amplification have been
described. One in which amplification results from a nonlinearity in the transduction
mechanism itself [8-10] and another in which the hair cell receptor potential drives a novel
motile process within the lateral membrane of the OHC soma [11]. In this scenario,
hyperpolarization causes the cell to expand along its longitudinal axis and depolarization causes
it to contract. Somatic electromotility of OHCs, as the basis for cochlear amplification, is a
mammalian novelty and is mediated by the motor-protein prestin [12], a member of the solute
carrier anion-transport family 26 (SLC26) that has undergone Darwinian selection only in the
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mammalian lineage [13,14]. The contribution of transduction nonlinearity to amplification in
the mammalian cochlea is still a matter of debate.
4. Amplification is under the control of the medial olivocochlear system
The MOC efferents (Figure 1A) originate in the medial portion of the superior olivary complex
and project to of the organ of Corti, where they form large synaptic contacts with OHCs (Figure
1A and B) [2]. Activation of the MOC pathway reduces cochlear sensitivity and tuning in a
frequency selective manner, by inhibiting the mechanical amplification of low-level sounds
that occurs before the sound stimulates the IHCs and the auditory nerve fibers [2, 15].
Olivocochlear efferent neurons permit the central nervous system to control the way that sounds
are processed in the auditory periphery, offering the potential to improve the detection of
signals in background noise [16-18], to selectively attend to particular signals [19, 20], and to
protect the periphery from damage caused by overly loud sounds [21-25].
5. The nicotinic cholinergic receptor of cochlear hair cells
Acetylcholine (ACh) is the principal neurotransmitter released by MOC terminals. While both
muscarinic and nicotinic receptors have been proposed to mediate the effects of ACh in the
cochlea, pharmacological and electrophysiological data suggest a central role for an atypical,
nAChR located at the synapse between efferent fibers and OHCs [15,26-34]. Current data
indicates that activation of the hair cell nAChR leads to an increase in intracellular Ca2+ and
the subsequent opening of small conductance Ca2+-activated K+ (SK2) channels, thus leading
to hyperpolarization of hair cells (Figure 2) and reduction of electromotility [33-36].
The cloning of the α9 nicotinic cholinergic receptor subunit deciphered the ionotropic
molecular nature of the hair cell cholinergic receptor and established its inclusion within the
nicotinic family of cholinergic receptor subunits [37]. The generation of mice carrying a null
mutation for the gene encoding the α9 subunit (Chrna9) has unequivocally demonstrated that
this subunit is a main component of the native OHC cholinergic receptor [38]. Characterization
of the rat α9 nAChR subunit revealed that it formed homomeric, calcium-permeable, ACh-
gated channels when expressed in Xenopus laevis oocytes with pharmacological properties
largely indistinguishable from those reported for the native hair cell cholinergic receptor [37,
39-41]. Moreover, a combination of in situ hybridization and reverse transcription-polymerase
chain reaction (RT-PCR) experiments have shown α9 transcripts in cochlear and vestibular
hair cells of several vertebrate species [37,42,43].
The cloning of the α9 subunit added a peculiar member to the nicotinic family of receptor
subunits. When expressed in Xenopus laevis oocytes, α9 forms a homomeric receptor-channel
complex that is activated by ACh, but displays a very distinct pharmacological profile. This
matches neither the nicotinic nor the muscarinic subdivision of the pharmacological scheme
of cholinergic receptors, and in addition has sensitivities in common with GABAA, glycine
and 5HT3 receptors [40]. Moreover, α9 is a distant member of the nAChR family with an amino
acid sequence identity compared to all known nicotinic subunits (other than α10) of less than
39%. This, taken together with the fact that the structure of the gene that encodes the α9 nAChR
(Chrna9) subunit differs from that of all known genes coding for nAChR subunits [26,29,37,
44], indicates that α9 represents an early divergent branch closer to the ancestor that gave rise
to the nicotinic gene family [45,46].
With the cloning of α9, the working hypothesis was that the α9 nicotinic subunit, functioning
as a homopentameric acetylcholine-gated channel, was the native hair cell cholinergic receptor.
However, three properties of homomeric α9 receptors properties did not match those seen in
isolated hair cells: the current-voltage relationship, the Ca2+ sensitivity and the desensitization
kinetics [26,29,44]. The cloning of the α10 nAChR from cochlear libraries and the expression
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of both α9 and α10 in Xenopus laevis oocytes demonstrated that the α9α10 receptor thoroughly
recapitulates the pharmacological and biophysical properties of hair cell nAChR [47-49].
Moreover, the generation of Chrna10 null mutant mice has indicated that, while functional
homomeric α9 channels are present in OHCs of these genetically modified mice, they are
insufficient to drive normal MOC efferent inhibition to the cochlea, demonstrating that the
α10 subunit is also an essential component of the hair cell nAChR [50]. Thus, it is now believed
that the hair cell cholinergic receptor that mediates synaptic transmission between efferent OC
fibers and hair cells of the cochlea, is formed by both α9 and α10 subunits, in a pentameric
structure with a most likely (α9)2(α10)3 stoichiometry [37,47,51].
An interesting feature of the α9 and α10 nAChR subunits is their evolutionary history [14].
The introduction of a descending fiber pathway to the inner ear occurred early in evolution,
predating the emergence of terrestrial life and is a common feature among all vertebrates [2].
Therefore, one would expect similar evolutionary histories of the genes coding for the α9 and
the α10 subunits across all vertebrate lineages. Intriguingly, while Chrna9 has been under
strong purifying pressure throughout vertebrates, Chrna10 shows signs of positive Darwinian
selection only along the lineage leading to mammals [14]. This suggests that mammalian
α9α10 nicotinic receptors probably acquired a novel function that evolved in conjunction with
properties specific to mammalian hearing. Co-varying with the evolutionary history of
Chrna10 is prestin, the protein responsible for somatic electromotility of mammalian OHCs,
which has also been under positive selection pressure only in mammals [14]. Thus, it is
tempting to speculate that Chrna10 has evolved to give the mammalian auditory system
feedback control of prestin-driven somatic electromotility, a capacity that is not required in
non-mammalian species.
6. The α9α10 nAChR and pathologies related to the auditory pathway. A target
for pharmacological intervention?
6.1. Hearing Loss
Millions of people the world round have hearing loss or associated conditions, such as tinnitus,
otitis media and Ménières disease. According to the World Health Organization 250 million
people worldwide have a moderate-to-severe or greater hearing loss
(www.who.int/pbd/deafness/facts/en/index.html). This figure more than doubles if people with
mild hearing loss are included. Hearing impairment is one of the most common sensory
disabilities, and may drastically limit the quality of life, with an incidence of 1:1000 in
newborns. It becomes increasingly prevalent with age. Hearing loss affects approximately 17
in every 1000 children under the age 18, approximately 314 in 1000 adults over age 65, and
40–50% of people 75 and older. The Royal National Institute for Deaf People, UK
(www.rnid.org.uk), estimates that there are over 300 million people in the world with age-
related hearing loss and this is expected to increase to 900 million by 2050 [52]. It is the third
most common chronic condition in the older population (after arthritis and high blood pressure)
[52].
Hearing loss is a social and economic burden. It can cause considerable difficulties in
communication with the outside world in general and lead to sadness, depression, anxiety,
social isolation, and insecurity [53]. To function in a hearing society, hearing-impaired persons
require specialized education, social services, and other resources. Children who are born
profoundly deaf face severe difficulty acquiring spoken language and are often taught in special
schools. Severe to profound hearing loss is expected to cost society $297,000 over the lifetime
of an individual. Most of these costs (67%) are due to reduced work productivity, although the
use of special education resources among children contributes an additional 21%. Lifetime
costs for those with prelingual onset of deafness exceed $1 million [54].
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Hearing loss is caused by several environmental and genetic factors and the proportion
attributed to inherited causes is thought to be at least 50% [55,56]. Progress in identifying genes
involved in deafness has been remarkable over the past few years. At the end of 1996, no non-
syndromic deafness genes had been cloned. In the 12 years since then, almost 50 new genes
involved in non-syndromic deafness have been identified, together with an even larger number
of genes implicated in syndromic deafness [55]. Whereas single-gene defects probably account
for over half of the cases of childhood deafness, the nature of the genetic contribution to
progressive and age-related hearing loss has not yet been clearly defined. So far, over 100 loci
involved in non-syndromic deafness have been reported (The Hereditary Hearing loss
Homepage, http://webh01.ua.ac.be/hhh/) and over 400 distinct syndromes including hearing
impairment are listed in Online Mendelian Inheritance in Man
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim). Thus, there are many more genes
awaiting identification.
Mutations in Chrna9 and Chrna10 associated with hearing impairment have not been identified
so far. Human Chrna9 and Chrna10 are localized to chromosomes 4p14 and 11p15.5,
respectively (Ensembl, www.ensembl.org). In addition, no non-syndromic loci have been
linked near the Chrna9 locus (The Hereditary Hearing loss Homepage,
http://webh01.ua.ac.be/hhh/). As reported in the The Hereditary Hearing loss Homepage
(http://webh01.ua.ac.be/hhh/) a genetic linkage study conducted on a large multigenerational
US family with non-syndromic autosomal dominant progressive hearing loss resulted in the
localization of a deafness locus, DFNA32. The deafness gene segregating in this family was
mapped to the telomere region of chromosome 11p15 with a maximum lod score of 4.1 with
marker D11S1984 (The Hereditary Hearing loss Homepage, http://webh01.ua.ac.be/hhh/). No
further studies have been performed which narrow down the locus or identify a candidate gene.
This genetic marker is 2 cM away from the Chrna10 locus, pinpointing Chrna10 as a candidate
gene. However, the fact that in Chrna9 and Chrna10 knockout mice the basal auditory function
is normal [38,50], might indicate that no major hearing impairment is expected from mutations
which lead to loss of function of the α9α10 nAChR. Gene knockout experiments have the
drawback that compensatory expression of other genes might obscure a clear interpretation.
Alternative experiments in which the efferent system has been sectioned have indicated
alterations in cochlear functioning. In an anatomical study, Pujol and Carlier [57] sectioned
the OC bundle in neonatal cats and reported that the afferent innervation of OHCs failed to
develop normally. They suggested that the normal arrival of MOC terminals at the OHCs during
postnatal development is necessary to effect the pruning of exuberant afferent contacts in the
OHC area. In a physiological study, Walsh and McGee [58] showed that transection of the OC
bundle in neonatal cats eliminates the rhythmic responses normally seen in the spike trains of
immature auditory neurons and suggested that the OC bundle may play a role in culling
exuberant contacts between IHCs and their afferents. Both results are consistent with the idea
that the OC bundle plays a role during cochlear development. Moreover, cats de-efferented
shortly after birth show increased characteristic frequency-threshold, broadened tuning, and
compressed spontaneous rates in adulthood [59], indicating that the OC system provides
developmental influences necessary for the acquisition of normal adult cochlear function. It
should be noted that during early developmental stages cholinergic OC fibers project to the
IHC region where they make direct contacts with these cells [60]. The fact that the efferent
synaptic activity during this developmental period is mediated through α9α10 nAChRs
[60-62], indicates that the developmental effects of the OC system are due to the activation of
these receptors. It still remains to be established in humans whether alterations in the efferent
system during early developmental periods lead to similar cochlear developmental
abnormalities and if mutations in either Chrna9 and/or Chrna10 lead to hearing impairment.
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6.2. Noise-Induced Hearing Loss
Noise is the greatest causative factor among the defined etiologies of hearing loss. Since the
industrial revolution, an increasing number of people are being exposed to extreme levels of
noise. Noise at levels 85 dBA and higher can lead both to mechanical and metabolic damage
of the cochlea [63,64]. Single, repeated or continuous exposure to high levels of noise can
cause Noise-Induced Hearing Loss (NIHL, Table 1). Since millions of people are daily exposed
to harmful levels of noise, NIHL is one of the most important workplace hazards. Occupations
such as the military [65-67], construction [68-70], mining [71], forestry [72], farming [73],
aviation [74-76], rail [77,78] and trucking [79,80] report the urgent need to develop hearing
conservation programs. In addition, recreational noise, like attending rock concerts or discos
or the use of MP3 players, reach sound pressure levels in the dangerous zone [81,82]. The
efficacy of hearing-protection devices (e.g. earplugs) and hearing-protection measures (i.e.
reduced noise exposure time) could be augmented by pharmacological agents that might reduce
NIHL more effectively, reducing the compensation costs associated with NIHL across all
industries [83].
At present, there is no FDA-approved drug product that can reduce or prevent NIHL. However,
animal work has demonstrated that different compounds acting on several biochemical
pathways are effective in preventing NIHL [83]. This include agents that reduce the
concentration of reactive oxygen species, reactive nitrogen species and free radicals [84],
glutathione precursors [85], agents that prevent hair cell apoptosis by disrupting mitogen-
activated protein kinase (MAPK) cell death signaling through peptide inhibition of c-Jun N-
terminal Kinase [86], drugs like ebselen that mimic the effect of glutathione peroxidase [87]
and NMDA receptor antagonists [88,89]. A few compounds are in the pharmaceutical pipeline,
like ebselen (Phase II, Sound Pharmaceuticals) and the JNK MAPK-mediated apoptosis
blocker AM-111 (Phase II, Auris Medical).
Compounds that augment the effect of the MOC system to the OHCs appear as an alternative
strategy to prevent NIHL. Many studies have implicated OC feedback in protecting the cochlea
from acoustic injury: electrical stimulation of the OC bundle reduces temporary threshold shifts
from acoustic overexposure [90] and chronic section of the OC bundle renders the ear more
vulnerable to permanent acoustic injury [91,92]. In mice, an assay that measures the strength
of this sound-evoked OC feedback pathway to the inner ear, has shown that it is inversely
correlated with the degree of hearing loss after subsequent noise [22]. That the medial branch
of the OC system is involved in protection has been demonstrated in a transgenic mice that
overexpress the α9 nAChR subunit [23]. Moreover, a knockin mouse engineered to
accommodate a leucine for threonine substitution at position 9′ of the second transmembrane
region of the α9 subunit, has a pronounced prolongation of efferent synaptic currents, a
dramatic increase in the MOC effect as assessed by electrical stimulation of efferent axons in
the floor of the IVth ventricle, and increased auditory thresholds [25]. In addition, this sole
mutation renders mice more resistant to permanent NIHL. These results confirm that protection
by MOC feedback depends explicitly on activation of the hair cell's α9α10 nAChR and
indicates that the nAChR itself could be modulated to provide therapeutic protection. In
addition, it gives some hints concerning the properties of a possible otoprotectant drug, since
in the mutant mice nAChRs have decreased desensitization kinetics plus increased agonist
apparent affinity [25].
6.3. Tinnitus
Tinnitus (commonly referred to as ringing in the ears or head) is often one of the first signs of
potential damage to hearing, especially after exposure to loud noise. One in 10 adults have
clinically significant tinnitus (regular prolonged spontaneous tinnitus lasting 5 minutes or
more), and for 1 in 100 tinnitus severely affects their ability to lead a normal life [93-95].
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Estimates indicate that 13 million people in western Europe and the USA currently seek medical
advice for their tinnitus [52]. Over 4 million prescriptions are written each year for tinnitus
relief, but these are all for off-label drugs from a wide variety of therapeutic classes and most
are associated with considerable side effects. Despite the significant unmet clinical need for a
safe and effective drug targeting tinnitus relief, there is currently no FDA-approved drug on
the market. The Royal National Institute for Deaf People, UK, estimates that a novel tinnitus
drug could have a product value of US$689 million in its first year of launch [52].
There are very few drugs in clinical trials for tinnitus. One that has reached Phase III is
neramexane, from Merz Pharmaceuticals Gmbh (www.clinicaltrials.gov). Neramexane was
developed as a follow up to memantine used for Alzheimer disease. Like memantine,
neramexane was studied in individuals with moderate to severe Alzheimer disease, but it did
not meet its primary endpoint efficacy measurements of SIB (Severe Impairment Battery) and
ADCS-ADLsev (ADCS-ADL severe subset) when tested in Phase III trials in combination
with cholinesterase inhibitors. A second Phase III trial as monotherapy showed statistical
significance for neramexane in individuals with moderate to severe disease; the primary
endpoint of this trial was efficacy measurement of ADCS-ADL, and further Phase III studies
are under way [96]. As memantine's patent is expected to expire in 2010, neramexane may be
an early follow-on product and must show a level of differentiation over memantine if it is to
succeed. Nonetheless, with a number of other indications also in development for neramexane
(including neuropathic pain, tinnitus and alcohol dependence), it is clear there is commitment
from Merz behind it [96].
According to the information provided in the clinical trial web site (www.clinicaltrials.gov),
it is proposed that neramexane may alleviate tinnitus symptoms due to its NMDA [97] and
α9α10 [98] nAChR blocking activities. Although early on tinnitus was considered an inner ear
disorder, it is now clear that chronic tinnitus is due to neuronal abnormalities in the central
nervous system [99]. Thus, it is difficult to envision how targeting a receptor expressed in the
inner ear might be beneficial for chronic tinnitus. One possible explanation might result from
the fact that in those patients where tinnitus is associated with hearing loss, tinnitus is alleviated
when hearing impairment is reduced. This is the case for patients with hearing loss and tinnitus
that have been cochlear implanted [100]. Thus, blockage of α9α10 receptors could increase
cochlear amplification by decreasing the activity of the MOC feedback effector system and
therefore α9α10 antagonists might be beneficial for the treatment of tinnitus, most likely in
conjunction with some central nervous system acting drug. Possible side effects as the result
of the blockade of α9α10 nAChRs, such as increased sensitivity to NIHL, should be taken into
account.
6.4. Auditory processing disorders
Failure to acquire adequate reading skills (reading being slower or less accurate than expected
for age) is one of the most common neurobehavioral problems affecting children. Dyslexic
children have an impairment of the development of the phonetic skills necessary to identify
and properly use the constituent sounds of written words, due to a temporal processing deficit
that affects the sensory input needed for the proper phonological coding critically required for
reading [101,102]. These deficits are aggravated in the presence of background noise,
suggesting that a noisy environment, such as often prevails in the classroom, is particularly
deleterious for such children [103,104].
The neural mechanisms underlying speech intelligibility-in-noise have not yet been well
identified, but the MOC system probably plays a role. Animal studies have shown that efferent
bundle activation can improve hearing-in-noise by exerting an antimasking effect [17,105]. In
humans, weak MOC functioning is correlated with poor tone detection in background noise
[106-109] and reduced speech intelligibility-in-noise in both adults [110] and children [111].
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Moreover, impaired MOC system functionality in learning-impaired children, in a context of
multiple phonemic confusion between voiced/voiceless phonemes, has been described [112].
In addition, the MOC system has been shown to function more strongly in professional
musicians [108,113], suggesting the possibility that sound conditioning could strengthen these
auditory descending pathways. Indeed, intensive auditory training has been shown to increase
MOC activity, and to improve speech perception [114]. MOC activity measured on the first
training day strongly predicts the subsequent amount of improvement, such that weaker initial
MOC activity is associated with greater improvement [115]. Thus enhancing MOC strength
in addition to auditory training might emerge as a strategy to treat dyslexic children. In this
context, drugs that enhance α9α10 nAChR activity might be of therapeutic benefit.
7. Targeting α9α10 nAChRs
The evidence that nAChRs play a role in a number of different neural functions and disorders
has given impetus to the search for drugs that selectively affect different receptor subtypes.
However, the recent findings indicating that native receptors are much more heterogeneous
than previously thought [116], has hampered the development of receptor-specific compounds
[117]. This difficulty is most likely overcome in the case of α9 and α10-containing nAChRs,
since these subunits appear only to assemble with each other and not with any of the other
nAChR subunits [37,47].
Nicotinic receptor ligands can be classified into three main classes: a) agonists, b)
antagonists, and 3) allosteric modulators, which may stimulate or inhibit nAChR function by
binding to regulatory sites other than ACh binding sites [117,118]. As discussed above, the
design of α9α10 selective agonists would be beneficial in the case of NIHL and as an adjuvant
in auditory training of dyslexic children. However, very few compounds have been reported
as agonists of α9α10 receptors. Most classical nAChR agonists, such as nicotine, cytisine and
epibatidine are antagonists of this receptor subtype [41]. Thus, positive allosteric modulators
emerge as good candidates to enhance receptor activity. Moreover, although nicotinic agonists
have shown some beneficial effects in treatment of central nervous system disorders, chronic
treatment of humans with such compounds has not been thoroughly characterized and may
provide suboptimal benefit because of sustained activation and/or desensitization of the target
receptor [119,120]. A different approach would be to administer a nicotinic receptor positive
allosteric modulator that can reinforce the endogenous cholinergic neurotransmission without
directly stimulating the target receptors [121]. Several positive allosteric modulators have been
described in the case of α7 nAChR [122]. In particular, PNU-120596 not only increases
maximal amplitude and potency of ACh-evoked α7 nAChR current by several fold, but also
almost suppresses desensitization [123]. These characteristics are ideal for a compound
targeting α9α10 nAChRs with the aim of preventing cochlear damage produced by intense
noise, since they mimic the effects rendered by the leucine for threonine mutation used to
generate the α9 knockin mouse with enhanced resistance to NIHL [25]. The fact that the store
active compound ryanodine potentiates α9α10-mediated ACh-responses [124], opens a
possible avenue for the design of positive allosteric modulators of this receptor subtype.
Finally, if blockade of α9α10 nAChRs would eventually result in a valid strategy to alleviate
tinnitus, a wide variety of compounds could be designed. α9α10 nAChRs are not only blocked
by nicotinic and muscarinic receptor antagonists [37,41,47], but also by compounds that block
other members of the family of Cys-loop receptors [40,125]. Thus, compounds like tropisetron
and ondansetron that are already used in clinical settings for other conditions and which have
high potency on α9α10 receptors [125], would be likely first candidates.
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8. Conclusions
Much has been learned over the last 60 years concerning the properties and function of the
efferent system to the cochlea, beginning with its first description [4], the characterization of
the effects of ACh on isolated hair cells [32,34], to the cloning of the atypical cholinergic
receptor of hair cells [37,47]. The following years will probably witness the design of hair cell
nAChR-based therapies. This most likely will include drugs to prevent NIHL, to alleviate
tinnitus and to treat auditory processing disorders.
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gene that codes for the α9 nAChR subunit
Chrna10  
gene that codes for the α10 nAChR subunit
IHCs  
inner hair cells
MOC  
medial olivocochlear
nAChRs  
nicotinic acetylcholine receptors
NIHL  
noise-induced hearing loss
OC  
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OHCs  
outer hair cells
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Figure 1.
Schematics showing the central origin (A) and peripheral projections (B) of the MOC fibers
and the cholinergic synapse onto OHCs in the mature organ of Corti (C). MOC efferent neurons
are located in the superior olivary complex of the brainstem and project to the cochlea, where
they make direct synaptic contacts at the base of the OHCs. At this synapse ACh is released.
It binds to α9α10 receptors present at the OHCs, leading to Ca2+ influx and the subsequent
activation of Ca2+-dependent SK2 K+ channels and hair cell hyperpolarization. The arrow in
A indicates the place of electrical stimulation to activate the MOC fibers. The white arrow in
B, indicates the afferent fibers which bring information from the IHCs to the central nervous
system and the red arrow the MOC fibers. For approximately ten days after birth (before the
onset of hearing), cholinergic efferents temporarily synapse directly with IHCs and the
cholinergic receptors at that synapse are also of the α9α10 subtype (not shown). Reproduced
from Taranda et al., PLoS Biology, 7(1):e18: 71-83, 2009.
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Figure 2.
Whole cell patch clamp used to record efferent synaptic currents from OHCs in the organ of
Corti ex vivo. Upper panel shows a patch pipette attached to a first row OHC in the apical turn
of a postnatal day 16 rat cochlea. Lower panel shows the typical biphasic synaptic current (-60
mV holding potential) produced by spontaneous ACh release from the presynaptic efferent
terminal. It has been demonstrated that this biphasic current flow results from the sequential
activation of α9α10-containing nAChRs, followed by calcium-gated (SK) potassium channels.
Micrograph and recording courtesy of M. Lioudyno.
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Table 1
Maximal Sound Pressure Levels (SPLs), durations and sources that can irreversibly damage hearing (The National
Institute for Occupational Safety and Health, http://www.cdc.gov/NIOSH/).
SPL Duration Source
140 dB < 1 min firearms, jet planes
130 dB > 1 min jackhammers
120 dB > 5 min amplified car stereo
110 db > 15 min rock concerts, planes
100 dB > 1 hr woodshops, chainsaws
90 dB > 4 hr motorcycles, lawnmowers
85 dB > 8 hr interior plane cabins
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